Novel distribution of cluster of differentiation 200 adhesion molecule in glial cells of the peripheral nervous system of rats and its modulation after nerve injury

Neuroscience ◽  
2011 ◽  
Vol 183 ◽  
pp. 32-46 ◽  
Author(s):  
C.-Y. Chang ◽  
Y.-H. Lee ◽  
Y.-F. Jiang-Shieh ◽  
H.-F. Chien ◽  
M.-H. Pai ◽  
...  
Development ◽  
2000 ◽  
Vol 127 (17) ◽  
pp. 3735-3743 ◽  
Author(s):  
V. Van De Bor ◽  
R. Walther ◽  
A. Giangrande

In flies, the choice between neuronal and glial fates depends on the asymmetric division of multipotent precursors, the neuroglioblast of the central nervous system and the IIb precursor of the sensory organ lineage. In the central nervous system, the choice between the two fates requires asymmetric distribution of the glial cell deficient/glial cell missing (glide/gcm) RNA in the neuroglioblast. Preferential accumulation of the transcript in one of the daughter cells results in the activation of the glial fate in that cell, which becomes a glial precursor. Here we show that glide/gcm is necessary to induce glial differentiation in the peripheral nervous system. We also present evidence that glide/gcm RNA is not necessary to induce the fate choice in the peripheral multipotent precursor. Indeed, glide/gcm RNA and protein are first detected in one daughter of IIb but not in IIb itself. Thus, glide/gcm is required in both central and peripheral glial cells, but its regulation is context dependent. Strikingly, we have found that only subsets of sensory organs are gliogenic and express glide/gcm. The ability to produce glial cells depends on fixed, lineage related, cues and not on stochastic decisions. Finally, we show that after glide/gcm expression has ceased, the IIb daughter migrates and divides symmetrically to produce several mature glial cells. Thus, the glide/gcm-expressing cell, also called the fifth cell of the sensory organ, is indeed a glial precursor. This is the first reported case of symmetric division in the sensory organ lineage. These data indicate that the organization of the fly peripheral nervous system is more complex than previously thought.


Glia ◽  
2006 ◽  
Vol 53 (7) ◽  
pp. 783-787 ◽  
Author(s):  
Hongwen Gao ◽  
Chengyan He ◽  
Xuedong Fang ◽  
Xia Hou ◽  
Xuechao Feng ◽  
...  

Neuroreport ◽  
2001 ◽  
Vol 12 (7) ◽  
pp. 1403-1407 ◽  
Author(s):  
Norio Hashimoto ◽  
Hiroki Yamanaka ◽  
Tetsuo Fukuoka ◽  
Yi Dai ◽  
Koichi Obata ◽  
...  

2011 ◽  
Vol 33 (1) ◽  
pp. 75-83 ◽  
Author(s):  
Junling Yang ◽  
Yangyang Gu ◽  
Xiaodong Huang ◽  
Aiguo Shen ◽  
Chun Cheng

Development ◽  
1996 ◽  
Vol 122 (1) ◽  
pp. 131-139 ◽  
Author(s):  
S. Vincent ◽  
J.L. Vonesch ◽  
A. Giangrande

Glial cells constitute the second component of the nervous system and are important during neuronal development. In this paper we describe a gene, glial cell deficient, (glide), that is necessary for glial cell fate commitment in Drosophila melanogaster. Mutations at the glide locus prevent glial cell determination in the embryonic central and peripheral nervous system. Moreover, we show that the absence of glial cells is the consequence of a cell fate switch from glia to neurones. This suggests the existence of a multipotent precursor cells in the nervous system. glide mutants also display defects in axonal navigation, which confirms and extends previous results indicating a role for glial cells in these processes.


Development ◽  
2013 ◽  
Vol 140 (17) ◽  
pp. 3657-3668 ◽  
Author(s):  
C. M. von Hilchen ◽  
A. E. Bustos ◽  
A. Giangrande ◽  
G. M. Technau ◽  
B. Altenhein

Endocrinology ◽  
2008 ◽  
Vol 149 (12) ◽  
pp. 5963-5971 ◽  
Author(s):  
Kelli A. Sullivan ◽  
Bhumsoo Kim ◽  
Eva L. Feldman

IGF-I and -II are potent neuronal mitogens and survival factors. The actions of IGF-I and -II are mediated via the type I IGF receptor (IGF-IR) and IGF binding proteins regulate the bioavailability of the IGFs. Cell viability correlates with IGF-IR expression and intact IGF-I/IGF-IR signaling pathways, including activation of MAPK/phosphatidylinositol-3 kinase. The expression of IGF-I and -II, IGF-IR, and IGF binding proteins are developmentally regulated in the central and peripheral nervous system. IGF-I therapy demonstrates mixed therapeutic results in the treatment of peripheral nerve injury, neuropathy, and motor neuron diseases such as amyotrophic lateral sclerosis. In this review we discuss the role of IGFs during peripheral nervous system development and the IGF signaling system as the potential therapeutic target for the treatment of nerve injury and motor neuron diseases.


Sign in / Sign up

Export Citation Format

Share Document